Skip to main content
SpringerLink
Log in

Combination therapy of essential hypertension with pindolol (Visken) and hydralazine

  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Thirty patients suffering from essential hypertension were treated successively with placebo, hydralazine alone, and pindolol (Visken®) combined with hydralazine. Hydralazine caused a statistically significant reduction in blood pressure and an increase in pulse rate as compared with the placebo: palpitations were an irritating side-effect. The combination of hydralazine and pindolol resulted in an additional fall in blood pressure (p<0.001) and the pulse rate decreased (2 p<0.001). The combined treatment also had a favourable effect on palpitations and angina pectoris.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alarcon-Segovia, D., Wakum, K., Worthington, J., Emmerson, J.: Clincal and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosus. Medicine (Baltimore)46, 1–33 (1967)

    Google Scholar 

  2. Freis, E.D., Rose, J.C., Higgins, T.F.: The hemodynamic effects of hypotensive drugs in man. IV. 1-Hydrazinophthalazine. Circulation8, 199–204 (1953)

    Google Scholar 

  3. Freis, E.: Hemodynamics of hypertension. Physiol. Rev.40, 27–54 (1960)

    Google Scholar 

  4. Gilmore, E., Weil, J., Chidsey, C.: Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockade. New Engl. J. Med.282, 521–527 (1970)

    Google Scholar 

  5. Gottlieb, T., Katz, F., Chidsey, C.: Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension. Circulation45, 571–582 (1972)

    Google Scholar 

  6. Hansson, L., Orlander, R., Aberg, H., Malmcrona, R., Westerlund, A.: Treatment of hypertension with propranolol and hydralazine. Acta med. scand.190, 531–534 (1971)

    Google Scholar 

  7. Nickerson, M.: Antihypertensive agents and the drug therapy of hypertension. In: The pharmacological basis of therapeutics. Fourth edition. (eds. L. Goodman, L. Gilman), p. 728. New York: The Macmillan Company 1970

    Google Scholar 

  8. Persson, I., Ulrich, J.: Treatment of hypertension with a new beta-blocking agent, pindolol (Viskén). Europ. J. clin. Pharmacol.6, 217–219 (1973)

    Google Scholar 

  9. Prichard, B., Gillam, P.: Treatment of hypertension with propranolol. Brit. med. J.1969 I, 7–16

    Google Scholar 

  10. Sannerstedt, R., Stenberg, J., Vedin, A.: Chronic beta adrenergic blockade in hypertension. Amer. J. Cardiol.29, 718–723 (1972)

    Google Scholar 

  11. Shinebourne, E., Fleming, J., Hamer, J.: Effects of beta-adrenergic blockade during exercise in hypertensive and ischaemic heart-disease. Lancet1967 II, 1217–1220

    Google Scholar 

  12. Warren, D., Swainson, E., Wright, N.: Deterioration in renal function after beta-blockade in patients with chronic renal failure and hypertension. Brit. med. J.1974 II, 193–194

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Depts., Bispebjerg and Nörre Hopsitals, Copenhagen, Denmark

    I. Persson

Authors
  1. I. Persson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Persson, I. Combination therapy of essential hypertension with pindolol (Visken) and hydralazine. Eur J Clin Pharmacol 9, 91–93 (1975). https://doi.org/10.1007/BF00614002

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00614002

Key words

Search

Navigation